Use of siRNAs to prevent and treat influenza virus infection
Use of siRNAs to prevent and treat influenza virus infection
复制标题
DOI：
10.1016/j.virusres.2004.01.013
复制
发表时间：
2004-06-01
期刊：
影响因子：
5
通讯作者：
Chen, JZ
中科院分区：
文献类型：
--
作者：
Ge, Q;Eisen, HN;Chen, JZ
流感病毒是人类最常见的感染之一。在典型的一年中，美国有10-20%的人口感染流感病毒。导致多达四万人死亡目前的疫苗可以预防大约70-80%的65岁以下的健康个体的疾病，但在最容易感染的人群中，即婴儿，老年人和免疫功能低下的个体，保护率要低得多。尽管四种抗病毒药物已在美国被批准用于治疗和/或预防流感。由于担心副作用、依从性和可能出现耐药病毒，它们的使用受到限制。我们发现流感病毒基因组保守区域特异性的短干扰RNA（siRNA）是流感病毒在细胞系和含胚鸡蛋中复制的有效抑制剂。在这篇评论中。我们讨论了siRNA在预防和治疗人类流感病毒感染方面的潜在价值，以及实现其潜力所必须克服的挑战。(C)2004 Elsevier B. V.保留所有权利。
Influenza virus causes one of the most prevalent infections in humans. In a typical year, 10-20% of the population in the United States are infected by influenza virus. resulting in up to 40,000 deaths. Current vaccines can prevent illness in approximately 70-80% of healthy individuals under age 65, but the protection rate is much lower in those most susceptible to infection, namely infants, the elderly, and immunocompromised individuals. Although four antiviral drugs have been approved in the United States for treatment and/or prophylaxis of influenza. their use is limited because of concerns about side effects, compliance, and the possible emergence of resistant virus. We found that short interfering RNAs (siRNAs) specific for conserved regions of the influenza virus genome are potent inhibitors of influenza virus replication in both cell lines and embryonated chicken eggs. In this review. we discuss the potential value of siRNAs for preventing and treating influenza virus infections in humans and the challenges that have to be overcome to realize their potential. (C) 2004 Elsevier B.V. All rights reserved.